hrp0086p2-p514 | Fat Metabolism and Obesity P2 | ESPE2016

Prader Willi Syndrome in Brazil: 6 months Follow-up in a Reference Center

Ito Simone , Passone Caroline , Rocha Ruth , Dichtchekenian Vae , Kupperman Hilton , Damiani Durval

Background: Prader–Willi syndrome (PWS) patients have been followed in our country in different ways but without a reference center. In January 2015, we started a PWS reference center in Sao Paulo University to promote a better care for patients and families and to support them with a multidisciplinary team, including pediatric endocrinologist, dietician, nurses, neurologist specialized in sleep disorders and otorhinolaringologist.Method: Forty-two ...

hrp0082p2-d2-541 | Puberty and Neuroendocrinology (1) | ESPE2014

Normal Minipuberty in a Patient with DAX1 Mutation: a Reliable Marker of the Function of the Hypothalamic–Pituitary–Gonadal Axis?

Fudvoye Julie , Christine Lebrethon Marie , Pierre Bourguignon Jean , Simone Parent Anne

Background: We report here the case of a 5-week-old male patient, referred to the hospital because of failure to thrive. An adrenal insufficiency was diagnosed and the genetic testing showed a mutation in the DAX1 gene leading to a premature stop codon.In addition to adrenal hypoplasia congenita, DAX1 mutation is known to be classically associated with hypogonadotrophic hypogonadism which is mostly characterized by absence of onset of puberty and inferti...

hrp0084p3-836 | Fat | ESPE2015

Prader-Willi Syndrome – A General Picture of 51 Cases

Ito Simone , dos Santos Tiago Jeronimo , Passone Caroline , Franco Ruth , Damiani Durval

Objective and hypotheses: To describe the morphological characteristics of patients with Prader-Willi Syndrome (SPW) who have been followed in a Pediatric Endocrinology Outpatient Clinic.Method: We performed a retrospective study on 51 patients evaluating the age of diagnosis, genetic mutation, use of GH (rhGH), age of beginning of follow-up, and z-score of weight, height and BMI. Data on their first and latest visit to our clinic were compared....

hrp0084p3-1251 | Programming & Misc. | ESPE2015

Sexually Dimorphic Methylation of SF-1 in Rat Placenta after Gestational Exposure to BPA

Fudvoye Julie , Dehan Pierre , Lienard Mehdi , Trooskens Geert , Gerard Arlette , Bourguignon Jean-Pierre , Parent Anne-Simone

Background: Gestational exposure to endocrine disrupting chemicals (EDCs) can impact the control of sexual differentiation by altering the hormonal environment of the foetus. Prenatal exposure to BPA, for instance could lead to disorders of sexual development. At the interface between the mother and the foetus, the placenta plays a key role in foetal programming and responds to environmental stressors in a sex specific manner. Epigenetics has appeared to be a key mechanism for...

hrp0084p3-877 | Fat | ESPE2015

Higher Hb1Ac in Obese Prader-Willi Syndrome Patients vs Obese Controls

Passone Caroline , dos Santos Tiago Jeronimo , Ito Simone Sakura , Ybarra Marina , Cominato Louise , Franco Ruth , Damiani Durval

Background: Obesity in Prader-Willi Syndrome has peculiar features associated to reduced lean body mass which could confer different metabolic characteristics.Objective and hypotheses: The aim of this study is to describe and to compare the metabolic profile in obese patients and obese Prader-Willi syndrome patients (OPWS) followed in a Pediatric Endocrinology outpatient clinic.Method: 45 obese and 22 OPWS patients between 8 and 20...

hrp0097p1-490 | GH and IGFs | ESPE2023

Phenotype and genotype of children with biallelic GHRHR gene mutations: a Belgian case series

Van de Velde Simone , Boros Emese , Brunelle Chloë , Beckers Dominique , De Schepper Jean , Thomas Muriel , Heinrichs Claudine , Brachet Cécile

Background: Children with biallelic GHRHR gene pathogenic variants share a phenotype of growth failure starting in infancy and resulting in a proportionate short stature and bone age delay due to a complete isolated growth hormone (GH) deficiency. The genotype ranges from rare promotor mutations to the more frequent splicing mutations, some genotypes being specific to certain geographic areas. Diagnosis is mainly made around the age of 7 years and more often i...

hrp0095rfc11.4 | Late Breaking | ESPE2022

Are GnRH agonists beneficial in final adult height after 8 years old? Data from a Portuguese National Digital Platform of idiopathic Central Precocious Puberty

Espada Filipa , Castro Carolina , Luisa Leite Ana , Galo Elisa , Antunes Ana , Castro Sofia , Robalo Brigida , Amaral Daniela , Ferreira Sofia , Limbert Catarina

Objective: Central precocious puberty (CPP) is a common condition in pediatric endocrinology practice. Gonadotropin-releasing hormone agonists (GnRHa) treatment is safe, but the real effect on final height and the ideal timing for treatment remains controversial. The purpose of the authors was to evaluate a nationwide representative group of CPP Portuguese girls treated with GnRHa, assess the effectiveness of treatment and the growth outcome before and after 8...

hrp0095p1-541 | Multisystem Endocrine Disorders | ESPE2022

Severe Systemic Pseudohypoaldosteronism Type 1: 10 years of evolution

Luísa Carvalho Ana , Miguel Gomes Maria , Martins Sofia , Marques Olinda , Antunes Ana

Background: Type 1 pseudohypoaldosteronism (PHA1) is a rare syndrome characterized by unresponsiveness to aldosterone. Diagnosis is established by high levels of aldosterone and plasma renin activity, associated with findings of hypoaldosteronism (hyponatremia, hyperkalemia and metabolic acidosis). When the inheritance pattern is autosomal recessive it expresses as a severe systemic disease and the mortality rate is high, especially in the neonatal period....

hrp0095p2-177 | Growth and Syndromes | ESPE2022

Effects of Somatropin treatment in different groups of patients with indication for replacement therapy: isolated growth hormone deficiency, small for gestational age, Turner syndrome and Prader-Willi syndrome

Afonso Nuno , Luísa Carvalho Ana , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Somatropin has been the standard treatment for Growth hormone deficiency (GHD) since 1985. Nowadays, has been approved for the treatment of other diseases, as: Small for gestational age (SGA), Turner syndrome (TS) and Prader-Willi syndrome (PWS).Aims: Assess the efficacy of somatropin in children followed in a tertiary Hospital, at 12 and 24 months of treatment, and to compare the results based on the patie...

hrp0092p3-318 | Late Breaking Abstracts | ESPE2019

Novel Mutation in HNF4-Alpha Gene and Reclassification of Diabetes in a Family

Miguel Gomes Maria , Lemos Manuel C. , Marques Olinda , Martins Sofia , Antunes Ana

11-year-old female, admitted in the emergency room due to postprandial hyperglycemia (350 mg/dL) in her father´s glucometer without ketosis or acidosis. She referred one-month evolution of mild symptoms, as polydipsia, polyuria, sporadic abdominal pain and nocturia.She was the first child of non-consanguineous parents, born full term at vaginal delivery with a birth weight of 3760g (90th percentile). Since 5-years-old her weight was betwe...